drugset / Trial / NCT04925947
A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
Phase 2
Terminated
4 enrolled
Weill Medical College of Cornell University
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will assess the safety and efficacy of the study drug KN046 in patients with advanced thymic carcinoma who progressed after prior treatment with immune checkpoint inhibitor therapy.
Timeline
- Start
- 2021-12-13
- Primary completion
- 2023-05-05
- Completion
- 2023-05-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ERFONRILIMAB | Monoclonal antibody | 5 mg/kg | Intravenous |